Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Dose, Parallel-Group Study Of The Pharmacokinetics And Safety Of Bosutinib In Subjects With Renal Impairment And Matched Healthy Adults

NCT01233882 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01233882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01233882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Dose, Parallel-Group Study Of The Pharmacokinetics And Safety Of Bosutinib In Subjects With Renal Impairment And Matched Healthy Adults
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2010
Completion date
June 30, 2012
Enrollment
34 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

renal disease, end-stage, renal insufficiency, acute, renal insufficiency, chronic